Samsung’s partner, Biogen files patent infringement trial against Celltrion

Biogen Idec, the patentee of Mabthera(foreign name: Rituxan), applied for a judgment for the patent infringement against Celltrion.

Biogen is not only the second largest shareholder holding 9.7% of the entire Samsung Bioepis’ stocks, but a European partner that Samsung developed for biosimilars.

The patent judgment application is considered as an action to respond to the last year’s nullity j...